Related Experiment Video
Updated: Oct 24, 2025
10:30
Visualization of IL-22-expressing Lymphocytes Using Reporter Mice
Published on: January 25, 2017
9.0K
Interleukin-22: a potential therapeutic target in atherosclerosis
Jin-Wen Luo1, Yuan Hu2, Jian Liu1
1Department of Cardio-Thoracic Surgery, Hunan Children's Hospital, Changsha, 410007, People's Republic of China.
Molecular Medicine (Cambridge, Mass.)
|August 14, 2021
Summary
Interleukin-22 (IL-22) drives atherosclerosis development through various mechanisms. Targeting IL-22 signaling pathways presents a promising therapeutic strategy for this chronic inflammatory disease.
Area of Science:
- Immunology
- Cardiovascular Biology
- Molecular Medicine
Background:
- Atherosclerosis is a chronic immuno-inflammatory disease involving immune cell and lipid accumulation in the vascular wall.
- This review focuses on Interleukin-22 (IL-22), a cytokine implicated in inflammatory diseases.
Purpose of the Study:
- To review the latest advances in the regulation and signaling pathways of IL-22.
- To highlight the impact of IL-22 on the pathogenesis of atherosclerosis.
Main Methods:
- Literature review of recent studies on IL-22 and atherosclerosis.
- Analysis of IL-22's role in vascular cell function and inflammatory responses.
Main Results:
- IL-22, part of the IL-10 cytokine family, activates signaling pathways like JAK/STAT.
- IL-22 influences vascular smooth muscle cell proliferation, migration, angiogenesis, inflammation, hypertension, and cholesterol metabolism in atherosclerosis.
Conclusions:
- IL-22 promotes atherosclerosis through multiple mechanisms.
- IL-22 represents a potential therapeutic target for atherosclerosis treatment.
Related Concept Videos
01:24T Cell Types and Functions
1.6K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.6K
01:38Inflammation
56.6K
Overview
56.6K
01:26Atherosclerosis III: Management
75
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
75
01:20The JAK-STAT Signaling Pathway
9.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.7K